Bone targeting agents: bisphosphonates

被引:11
作者
Debiais, Francoise [1 ]
机构
[1] Univ Poitiers, CHU Poitiers, Serv Rhumatol, F-86021 Poitiers, France
关键词
bone metastases; bisphosphonates; malignant osteolysis; CANCER ADJUVANT THERAPY; LONG-TERM EFFICACY; BREAST-CANCER; ZOLEDRONIC ACID; AMERICAN-SOCIETY; SOLID TUMORS; DOUBLE-BLIND; TASK-FORCE; METASTASES; PAMIDRONATE;
D O I
10.1684/bdc.2013.1840
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant tumor osteolysis is a frequent complication in many cancers. It can cause skeletal-related events with alteration of quality of life and survival. Bisphosphonates play an important role in the management of this malignant osteolysis, via an inhibition of osteoclast-mediated bone resorption, and a potential direct antitumor activity. Their use constitutes an important therapeutic advance in patients with bone metastases so as to reduce or delay the appearance of these skeletal events. They are also useful for the treatment of hypercalcemia, which could arise in these patients. Their interest as adjuvant therapy before the onset of bone metastases is currently being evaluated.
引用
收藏
页码:1199 / 1206
页数:8
相关论文
共 32 条
  • [21] Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer
    Rennert, Gad
    Pinchev, Mila
    Rennert, Hedy S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) : 3577 - 3581
  • [22] Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO
  • [23] 2-L
  • [24] Mechanisms of disease: Mechanisms of bone metastasis
    Roodman, GD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) : 1655 - 1664
  • [25] Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
    Rosen, LS
    Gordon, DH
    Dugan, W
    Major, P
    Eisenberg, PD
    Provencher, L
    Kaminski, M
    Simeone, J
    Seaman, J
    Chen, BL
    Coleman, RE
    [J]. CANCER, 2004, 100 (01) : 36 - 43
  • [26] Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
    Rosen, LS
    Gordon, D
    Tchekmedyian, NS
    Yanagihara, R
    Hirsh, V
    Krzakowski, M
    Pawlicki, M
    de Souza, P
    Zheng, M
    Urbanowitz, G
    Reitsma, D
    Seaman, J
    [J]. CANCER, 2004, 100 (12) : 2613 - 2621
  • [27] Bisphosphonates - An update on mechanisms of action and how these relate to clinical efficacy
    Russell, R. Graham G.
    Xia, Zhidao
    Dunford, James E.
    Oppermann, Udo
    Kwaasi, Aaron
    Hulley, Philippa A.
    Kavanagh, Kathryn L.
    Triffitt, James T.
    Lundy, Mark W.
    Phipps, Roger J.
    Barnett, Bobby L.
    Coxon, Fraser P.
    Rogers, Michael J.
    Watts, Nelson B.
    Ebetino, Frank H.
    [J]. SKELETAL BIOLOGY AND MEDICINE, PT B: DISEASE MECHANISMS AND THERAPEUTIC CHALLENGES, 2007, 1117 : 209 - 257
  • [28] Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Saad, F
    Gleason, DM
    Murray, R
    Tchekmedyian, S
    Venner, P
    Lacombe, L
    Chin, JL
    Vinholes, JJ
    Goas, JA
    Zheng, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) : 879 - 882
  • [29] Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research
    Shane, Elizabeth
    Burr, David
    Ebeling, Peter R.
    Abrahamsen, Bo
    Adler, Robert A.
    Brown, Thomas D.
    Cheung, Angela M.
    Cosman, Felicia
    Curtis, Jeffrey R.
    Dell, Richard
    Dempster, David
    Einhorn, Thomas A.
    Genant, Harry K.
    Geusens, Piet
    Klaushofer, Klaus
    Koval, Kenneth
    Lane, Joseph M.
    McKiernan, Fergus
    McKinney, Ross
    Ng, Alvin
    Nieves, Jeri
    O'Keefe, Regis
    Papapoulos, Socrates
    Sen, Howe Tet
    van der Meulen, Marjolein C. H.
    Weinstein, Robert S.
    Whyte, Michael
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (11) : 2267 - 2294
  • [30] American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer
    Van Poznak, Catherine H.
    Temin, Sarah
    Yee, Gary C.
    Janjan, Nora A.
    Barlow, William E.
    Biermann, J. Sybil
    Bosserman, Linda D.
    Geoghegan, Cindy
    Hillner, Bruce E.
    Theriault, Richard L.
    Zuckerman, Dan S.
    Von Roenn, Jamie H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1221 - 1227